Abiopharma

🔍 Heron Patrick J (Director)

Company: Arcutis Biotherapeutics, Inc. (ARQT)

Report Date: 2026-06-05

Detailed Transactions and Holdings:

• Acquired 5,778 shares of Common Stock (Direct)
  Date: 2026-06-05 | Code: A | equity_swap_involved: 0 | shares_owned_after: 32,213.00 | transaction_form_type: 4 | Footnotes: F1
• Holds 0 shares of Common Stock (Direct)
  Date: 2026-06-05 | Code: H | nature_of_ownership: By Frazier Life Sciences X, L.P. | shares_owned_after: 24,802.00 | Footnotes: F2
• Holds 0 shares of Common Stock (Direct)
  Date: 2026-06-05 | Code: H | nature_of_ownership: By Frazier Life Sciences VIII, L.P. | shares_owned_after: 8,785,284.00 | Footnotes: F3
• Holds 0 shares of Common Stock (Direct)
  Date: 2026-06-05 | Code: H | nature_of_ownership: By FHM Life Sciences VIII, L.L.C. | shares_owned_after: 7.00 | Footnotes: F4
• Holds 0 shares of Common Stock (Direct)
  Date: 2026-06-05 | Code: H | nature_of_ownership: By The Heron Living Trust 11/30/2004 | shares_owned_after: 23,688.00 | Footnotes: F5
• Acquired 16,667 shares of Stock Option (right to buy) at $21.23 per share (Derivative)
  Date: 2026-06-05 | Code: A | Expires: 2036-06-05 | equity_swap_involved: 0 | shares_owned_after: 16,667.00 | transaction_form_type: 4 | Footnotes: F6

Footnotes:

• F1: Represents Restricted Stock Units ("RSUs") granted in connection with the Reporting Person's service as a non-employee director as of the Company's 2026 annual meeting of stockholders. The Reporting Person is entitled to receive one (1) share of common stock for each one (1) RSU upon the vesting thereof, which shall occur on the earlier of the first anniversary of the grant date, June 5, 2026, or immediately before the next annual meeting of stockholders, subject to the continued service through the vesting date. Upon vesting of the RSUs, the settlement has been deferred by the Reporting Person, pursuant to the terms of the RSU Deferral Election Form adopted on October 21, 2025, maintained by the Company.
• F2: The shares reported herein are held of record by Frazier Life Sciences X, L.P. FHMLS X, L.P. is the general partner of Frazier Life Sciences X, L.P. and FHMLS X, L.L.C. is the general partner of FHMLS X, L.P. The Reporting Person is one of two managing members of FHMLS X, L.L.C. The Reporting Person disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of such securities for purposes of Section 16 or for any other purposes.
• F3: The shares reported herein are held of record by Frazier Life Sciences VIII, L.P. FHM Life Sciences VIII, L.P. is the general partner of Frazier Life Sciences VIII, L.P. and FHM Life Sciences VIII, L.L.C. is the general partner of FHM Life Sciences VIII, L.P. The Reporting Person is one of two managing members of FHM Life Sciences VIII, L.L.C. The Reporting Person disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of such securities for purposes of Section 16 or for any other purposes.
• F4: The shares reported herein are held of record by FHM Life Sciences VIII, L.L.C. The Reporting Person is one of two managing members of FHM Life Sciences VIII, L.L.C. The Reporting Person disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of such securities for purposes of Section 16 or for any other purposes.
• F5: The shares are held directly by The Heron Living Trust 11/30/2004. The Reporting Person is the co-trustee of The Heron Living Trust 11/30/2004 and has voting and investment power of the securities held by The Heron Living Trust 11/30/2004. The Reporting Person disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of such securities for purposes of Section 16 or for any other purposes.
• F6: The underlying shares subject to the option vest and become exercisable as to 100% on the earlier of the first anniversary of the grant date, June 5, 2026, or immediately before the next annual meeting of stockholders, subject to the continued service through the vesting date.